Member Profile
Formosa Laboratories
- C.Y. Cheng
- 1995/12/29
- 4746
- USD 257,691,350.0
- +886-3-324-0895
- 36 Hoping Street, Louchu, Taoyuan, Taiwan
- Immunology
- Infections and Infectious Diseases
- Neuroscience
- Oncology
- Pulmonary/Respiratory Diseases
- Small Molecule Drugs
- Biologics
- Biosimilars
- Vaccines
GDP Certificate
GMP Certificate
ISO 14001:2015
ISO 45001:2018
CNS 45001:2018
More information: https://www.formosalab.com/tw/inspection.php
Awards2015 Taipei Biotech Award, Go-Global Award, Silver Medal
2014 Taipei Biotech Award, Technology Commercialization Award, Silver Medal
2011 Taipei Biotech Award, Technology Commercialization Award, Silver Medal
2009 Taipei Biotech Award, Technology Commercialization Award, Gold Medal
2009 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Awards, Gold Medal
- Calcipotriol Monohydrate
- Sevelamer Carbonate
- Colesevelam HCl
Formosa Laboratories is a global API supplier. We provides GMP one-stop-shop CDMO services. The services ranges from small-molecule and polymer API to in-house payload-linker CMC services and antibody bio-conjugation for Antibody Drug Conjugate (ADC). We also offer aseptic liquid filling and lyophilization of both cytotoxic and non-cytotoxic injectables.
Company Milestones
| 2021 | Passed GMP inspection by TFDA for packaging and labeling of medicinal products. Passed GDP inspection by TFDA for medicinal products. |
| 2018 | Formosa’s customer in mainland China get the 1st Montelukast GQCE approval in Chinese mainland. |
| 2013 | Passed joint GMP inspection by EDQM and BGC Hamburg |
| 2010 | Passed 1st PAI for Mycophenolate Mofetil by COFEPRIS of Mexico |
| 2009 | Passed 1st PAI for Gadodiamide by PMDA of Japan |
| 2007 | Passed 1st GMP inspection by BSG of Hamburg, Germany |
| 2004 | Passed 1st PAI by US FDA for Leflunomide API |